Back to search

Article

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study

2022-09-23

Abstract excerpt

<h4>Background: </h4> Orelabrutinib is a novel, small molecule, selective irreversible Bruton’s tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy as well as safety in patients with refractory or relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL). <h4>Methods: </h4> This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8cc85bfa-bee8-5de6-8380-d83734f39657
DOI
10.21203/rs.3.rs-2087687/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudyDOI 10.21203/rs.3.rs-2087687/v1
Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohortSemantic proximity
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.Semantic proximity
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Semantic proximity
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity
Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.Semantic proximity
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity
SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.